Interleukin‐9 serves as a key link between systemic inflammation and angiogenesis in psoriasis

By Midde HS, Priyadarssini M, Rajappa M, et al
Published September 16, 2020

Key Takeaways

This study was undertaken to investigate interleukin (IL)‐9, IL‐17, and vascular endothelial growth factor (VEGF) levels in patients with psoriasis in comparison with controls, and to assess the impact of methotrexate (MTX) monotherapy on the aforesaid cytokine levels in psoriasis. Researchers conducted a cohort study recruiting a total of 54 patients with psoriasis and 54 age‐ and gender‐matched healthy controls (HCs). IL‐9, IL‐17, and by using commercially available ELISA kits, VEGF levels were assessed. The data imply the existence of a proinflammatory milieu in psoriasis, with elevated levels of IL‐9, IL‐17 and the proangiogenic growth factor VEGF, exhibiting an elevating trend with increasing disease severity and impaired quality of life (QoL). The data indicated that MTX treatment helps to decrease levels of IL‐9, IL‐17, and VEGF, thereby limiting disease progression and improving QoL in psoriasis.

Read the full article on Clinical and Experimental Dermatology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter